A Phase I Study of Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral KIF18A Inhibitor GenSci122 in Participants With Advanced Solid Tumors
Latest Information Update: 28 Jan 2025
Price :
$35 *
At a glance
- Drugs GenSci 122 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors GeneScience Pharmaceuticals
- 22 Jan 2025 Status changed from not yet recruiting to recruiting.
- 20 Jan 2025 New trial record
- 18 Dec 2024 According to a GenSci group media release, the company has received the "Drug Clinical Trial Approval Notice" approved and issued by the NMPA, agreeing to conduct clinical trials of the small molecule KIF18A inhibitor GenSci122 tablets for the treatment of advanced solid tumors. Previously, the project had been approved by the FDA IND.